US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.53

+0.33131.22%

Post-market: 27.530.00000.00%16:10 EDT

Volume:432

Turnover:11.78K

Market Cap:2.48M

PE:- -

High:27.53

Open:27.22

Low:27.22

Close:27.20

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.43

T/O Rate:0.48%

Dividend:0.68

Dividend Rate:2.47%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184

Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Opening Day: Scribe Therapeutics makes strong trading debut

Freenome, Abbott announce FDA approval of SimpleScreen CRC

Kura Oncology announces durable activity of darlifarnib combination in ccRCC

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

Healios Secures AMED Funding to Industrialize iPSC-Derived NK Cell Therapy

Chinese biotech overtakes AI as emerging-market growth trade

Srinivasan Sivabalan / Bloomberg

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Simply Wall St.

BB Biotech posts strong interim profit and shifts to yield-based dividend policy

South Korea's Q2 GDP Exceeds Expectations, Fueled by AI Chip Export Boom, Adding Pressure for Further Rate Hikes

CSPC Advances HPV mRNA Vaccine SYS6026 to Phase II Trial in China

NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS

Imunon announces new preliminary data from IMNN-001 trial

Biotech IPO gains crush AI listings with standout 55% return

Anthony Hughes / Bloomberg

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/NVIB/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.5312,"timestamp":1789761600000,"preClose":27.1999,"halted":0,"volume":432,"hourTrading":{"tag":"盘后","latestPrice":27.5312,"preClose":27.5312,"latestTime":"16:10 EDT","volume":6,"amount":165.1872,"timestamp":1789762204137,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01218019183894054,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Post-Mkt","change":0.3313,"latestTime":"09-18 16:54:17 EDT","open":27.215,"high":27.5312,"low":27.215,"amount":11784,"amplitude":0.011625,"askPrice":40.81,"askSize":200,"bidPrice":13.61,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.1999,"nav":26.486,"aum":2383782.07,"dividendRate":0.02471,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5312,"preClose":27.5312,"latestTime":"16:10 EDT","volume":6,"amount":165.1872,"timestamp":1789762204137,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.430193},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.430193,"shares":90001,"dividePrice":0.6803,"high":27.5312,"amplitude":0.011625,"preClose":27.1999,"low":27.215,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.5312,"eps":0,"divideRate":0.02471,"volume":432,"delay":0,"ttmEps":0,"open":27.215,"prevYearClose":25,"prevWeekClose":27.3696,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":27.3696,"twentyDayClose":27.0143},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654001704","title":"Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001704?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:50","pubTimestamp":1785239443,"startTime":"0","endTime":"0","summary":"Lantern Pharma (LTRN) announced that an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 in advanced, recurrent b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lantern-pharma-to-advance-ema-cleared-phase-1b-2-trial-of-lp-184-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","IDNA","BK4081","NVIB","HYLG","LTRN","BK4139","MEDX","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009072","title":"Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009072","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009072?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:40","pubTimestamp":1785238813,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics (DYN) announced that it has received clearance from the FDA for its IND application to initiate a Phase 1 clinical trial for DYNE...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyne-therapeutics-receives-fda-clearance-to-initiate-dyne-302-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","IDNA","BK4505","BK4585","HYLG","GDOC","DYN","NVIB","BK4588","DYNE","BK4139","IND","LABU","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043980","title":"Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043980","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043980?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"– ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334131/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Portfolio-Execution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4104","IDNA","BK4139","GDOC","HYLG","MEDX","RW","CAPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654730049","title":"Opening Day: Scribe Therapeutics makes strong trading debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2654730049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654730049?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:25","pubTimestamp":1785165946,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-scribe-therapeutics-makes-strong-trading-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","CRSP","SCTX","BK4611","IPOS","XBIX","NVIB","BK4556","BK4139","BK4585","SYNB","ARKG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010379","title":"Freenome, Abbott announce FDA approval of SimpleScreen CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010379","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010379?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:16","pubTimestamp":1785154580,"startTime":"0","endTime":"0","summary":"Freenome (FRNM) and Abbott (ABT) announced that the FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/freenome-abbott-announce-fda-approval-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/freenome-abbott-announce-fda-approval-of-simplescreen-crc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LU2324357040.USD","LU2112291526.USD","LU0868494617.USD","LU1691799644.USD","MRNY","LU2468319806.SGD","LU1721429402.USD","LFSC","LU0170899867.USD","IYH","FRNM","BK4588","BK4213","BK4504","MRNX","CRC","XLVX","TBXU","LU0266013472.USD","SGXZ41872573.SGD","NVIB","GDOC","TMED","FRTY","LU1061106388.HKD","IE0002141913.USD","SG9999002232.USD","BK4585","IBB","IHI","TECB","LABU","LU0266512127.USD","PSCH","SG9999002224.SGD","RSPH","PINK","ABT","IEIH","BBP","GNMX","IDNA","PJP","SYNB","LU1721429741.USD","MEDI","LU1914381329.SGD","LU2133065610.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011607","title":"Kura Oncology announces durable activity of darlifarnib combination in ccRCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654011607?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:40","pubTimestamp":1785148845,"startTime":"0","endTime":"0","summary":"Kura Oncology (KURA) announced updated Phase 1a results from the ongoing FIT-001 clinical trial demonstrating encouraging and durable clinical acti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-announces-durable-activity-of-darlifarnib-combination-in-ccrcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-announces-durable-activity-of-darlifarnib-combination-in-ccrcc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","HYLG","KURA","MEDX","GDOC","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654019247","title":"Ideaya Biosciences initiates monotherapy expansion in IDE892 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654019247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654019247?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:11","pubTimestamp":1785147099,"startTime":"0","endTime":"0","summary":"Ideaya Biosciences (IDYA) announced that initiation of Part 2 monotherapy expansion has been achieved in its Phase 1/2 clinical trial evaluating ID...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ideaya-biosciences-initiates-monotherapy-expansion-in-ide892-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ideaya-biosciences-initiates-monotherapy-expansion-in-ide892-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4139","MEDX","HYLG","IDYA","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654509632","title":"Healios Secures AMED Funding to Industrialize iPSC-Derived NK Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654509632","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654509632?lang=en_us&edition=fundamental","pubTime":"2026-07-27 10:52","pubTimestamp":1785120734,"startTime":"0","endTime":"0","summary":"Healios KK ( ($JP:4593) ) has issued an update. Healios K.K., a clinical-stage regenerative medicine biotech in Japan, is developing stem cell-base...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/healios-secures-amed-funding-to-industrialize-ipsc-derived-nk-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/healios-secures-amed-funding-to-industrialize-ipsc-derived-nk-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMED","XBIX","BK4196","JP","NVIB","LU1093756325.SGD","LU1093756168.USD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047803","title":"Chinese biotech overtakes AI as emerging-market growth trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047803","media":"Srinivasan Sivabalan / Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047803?lang=en_us&edition=fundamental","pubTime":"2026-07-27 06:33","pubTimestamp":1785105227,"startTime":"0","endTime":"0","summary":"As the artificial-intelligence rally sputters in emerging markets, investors searching for high-growth alternatives are turning to Chinese biotech.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/healthcare/chinese-biotech-overtakes-ai-emerging-market-growth-trade?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/healthcare/chinese-biotech-overtakes-ai-emerging-market-growth-trade?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["AIPO","QTOC","ARTY","KURE","AGIX","CHAT","XBIX","NVIB","QQQW","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654062712","title":"Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2654062712","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654062712?lang=en_us&edition=fundamental","pubTime":"2026-07-27 04:10","pubTimestamp":1785096654,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics signed a lease for a new headquarters and expanded manufacturing facility, contingent on US FDA approval of its Duchenne muscular dystrophy therapy, Deramiocel.\nThe planned space is significantly larger than the company’s current footprint, indicating a move to scale operations once regulatory conditions are met.\n\nCapricor Therapeutics, traded as NasdaqGS:CAPR, is drawing attention with this planned expansion linked directly to a key regulatory milestone. The stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-secures-new-headquarters-tied-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-capr/capricor-therapeutics/news/capricor-therapeutics-capr-secures-new-headquarters-tied-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","NVIB","CLR.SI","CAPR","SRT.SI","SRU.SI","BK4585","GLS.SI","CFA.SI","JJJ.SI","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270989","title":"BB Biotech posts strong interim profit and shifts to yield-based dividend policy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270989","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270989?lang=en_us&edition=fundamental","pubTime":"2026-07-24 13:34","pubTimestamp":1784871252,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BB Biotech ( ($CH:BION) ). BB Biotech AG, a specialist biotech investment company listed in Switzerland and Ger...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bb-biotech-posts-strong-interim-profit-and-shifts-to-yield-based-dividend-policy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bb-biotech-posts-strong-interim-profit-and-shifts-to-yield-based-dividend-policy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLT","VIG","TMF","XBI","US12M.BOND","NVIB","US5Y.BOND","LEAD","US3Y.BOND","US7Y.BOND","US30Y.BOND","US10Y.BOND","BK4588","BK4581","TLTW","XBIX","US2Y.BOND","BK4585","BK4547","BK4097","US6M.BOND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173039723","title":"South Korea's Q2 GDP Exceeds Expectations, Fueled by AI Chip Export Boom, Adding Pressure for Further Rate Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1173039723","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173039723?lang=en_us&edition=fundamental","pubTime":"2026-07-23 09:46","pubTimestamp":1784771209,"startTime":"0","endTime":"0","summary":"South Korea's economy grew more than anticipated in the second quarter, propelled by an artificial intelligence-driven boom in chip exports, a development that supports the case for the central bank...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMAU","PSAI","MULL","MUZ","MUD","MUYY","NVIB","MIC","LINT","MUU","INTW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653633037","title":"CSPC Advances HPV mRNA Vaccine SYS6026 to Phase II Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2653633037","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653633037?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:08","pubTimestamp":1784725684,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group has officially launched a Phase II clinical trial in Chi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cspc-advances-hpv-mrna-vaccine-sys6026-to-phase-ii-trial-in-china?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cspc-advances-hpv-mrna-vaccine-sys6026-to-phase-ii-trial-in-china?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","IDNA","NVIB","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653768188","title":"NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653768188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653768188?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:56","pubTimestamp":1784725011,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an update. NeuroSense Therapeutics, a late-stage clinical biotech developer of neurodegenera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurosense-moves-primec-toward-health-canada-drug-submission-for-als?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurosense-moves-primec-toward-health-canada-drug-submission-for-als?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720383","title":"Imunon announces new preliminary data from IMNN-001 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720383","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653720383?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:25","pubTimestamp":1784640328,"startTime":"0","endTime":"0","summary":"Imunon (IMNN) announced new preliminary data from its ongoing Phase 2 minimal residual disease, or MRD, translational clinical trial of IMNN-001, c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-announces-new-preliminary-data-from-imnn-001-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-announces-new-preliminary-data-from-imnn-001-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","BK4139","IDNA","NVIB","MEDX","IMNN","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653784051","title":"Biotech IPO gains crush AI listings with standout 55% return","url":"https://stock-news.laohu8.com/highlight/detail?id=2653784051","media":"Anthony Hughes / Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653784051?lang=en_us&edition=fundamental","pubTime":"2026-07-21 12:57","pubTimestamp":1784609865,"startTime":"0","endTime":"0","summary":"The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/us-stocks/biotech-ipo-gains-crush-ai-listings-standout-55-return?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/us-stocks/biotech-ipo-gains-crush-ai-listings-standout-55-return?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["KI","LRCY","VTHR","IJT","CHAT","QTOC","BK4588","BK4585","QQQJ","BK4127","AIPO","IPO","AGIX","TMFX","NVIB","BKIV","PEVC","XBI","REDS","ARTY","KCE","XBIX","FRHC","IPOS","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":196,"code":"91000000","status":"200"}]}}